quisinostat (JNJ 26481585) / J&J, Viriom, ChemRar  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
quisinostat (JNJ 26481585) / ChemRar, Viriom
NCT01486277 / 2011-001076-18: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Completed
2
26
US, Europe
Quisinostat, 12 mg, JNJ 26481585
Janssen Research & Development, LLC
Lymphoma, T-Cell, Cutaneous
11/14
07/16
NCT02948075: Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed
2
31
RoW
Quisinostat, JNJ-26481585, Paclitaxel, Carboplatin
NewVac LLC, Janssen Pharmaceutica N.V., Belgium
Ovarian Cancer
12/16
06/17

Download Options